The shifting tide: Private equity's accelerating footprint in healthcare services

Private equity continues to exert significant influence over the healthcare landscape, driving consolidation through aggressive acquisition strategies and financial restructuring. From revenue cycle management to clinical research and outpatient care, investors are increasingly placing capital into fragmented sectors, seeking to leverage scale for increased efficiency and profitability despite rising regulatory scrutiny.

Key takeaways

• Revenue cycle management (RCM) has become a primary target due to its high scalability and market necessity.

• Clinical research organizations are experiencing rapid roll-up activity, with key firms expanding their site counts to diversify trial focus.

• Private equity interest remains high in outpatient sectors like cardiology and dental care, which offer fragmented landscapes ideal for consolidation.

• Broader financial restructuring, including nonprofit-to-for-profit shifts and targeted asset sales, is being utilized by major insurers to streamline portfolios.

The rise of revenue cycle management consolidation

A noticeable trend in recent investment cycles is the focus on revenue cycle management (RCM). As medical and dental service organizations consolidate individual practices into larger platforms, the demand for sophisticated billing, accounts receivable management, and revenue optimization has surged. Companies such as Provana and Model N have become central components of this strategy, with firms like Long Ridge Equity Partners and Vista Equity Partners making significant acquisitions to capture a larger share of a global market projected to reach hundreds of billions by 2030.

Trends in clinical research and specialty investments

Clinical research is another sector where aggressive roll-up strategies are evident. Platforms like Pinnacle Clinical Research have transitioned from small-scale operations to multi-site networks by acquiring research centers focused on diverse medical conditions including liver disease, Alzheimer’s, and central nervous system research. This trend is driven by the highly fragmented nature of the industry and the inherent potential to resell larger, consolidated research networks at a premium. Investors have navigated economic headwinds by prioritizing growth and expansion investments, ensuring that clinical trials remain one of the more resilient segments of healthcare deal flow.

Strategic transformations in the broader healthcare landscape

Beyond individual acquisitions, the healthcare industry is seeing larger corporate restructuring efforts. Notable movements include significant shifts in the organizational structures of major Blue Cross insurance entities, as well as creative financial maneuvers by conglomerates like UnitedHealth Group, which has increasingly leveraged strategic asset sales to optimize earnings. These actions reflect a broader shift where insurers and medical service providers are reconsidering their asset holdings and long-term business models to remain competitive in a landscape increasingly defined by private investment and high-speed consolidation.

Sources

• M&A roundup: Platform, Springline, Sorren and Patrick expand, Accounting Today.

• Private Equity Health Care Acquisitions – June 2024, Private Equity Stakeholder Project PESP.

• Private Equity Healthcare Acquisitions – June 2023, Private Equity Stakeholder Project PESP.

• Blue Cross plans in NC, NJ form separate holding companies, Modern Healthcare.

• How UnitedHealth quietly boosted earnings with asset sales, Modern Healthcare.